[go: up one dir, main page]

BR9913190A - Modulação de proteìnas quinase de linhagemmúltipla - Google Patents

Modulação de proteìnas quinase de linhagemmúltipla

Info

Publication number
BR9913190A
BR9913190A BR9913190-0A BR9913190A BR9913190A BR 9913190 A BR9913190 A BR 9913190A BR 9913190 A BR9913190 A BR 9913190A BR 9913190 A BR9913190 A BR 9913190A
Authority
BR
Brazil
Prior art keywords
protein kinase
methods
compound
modulation
activity
Prior art date
Application number
BR9913190-0A
Other languages
English (en)
Inventor
Anna Maroney
Craig A Dionne
Ernest Knight
Kevin M Walton
Nicola Neff
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BR9913190A publication Critical patent/BR9913190A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)

Abstract

"MODULAçãO DE PROTEìNAS QUINASE DE LINHAGEMMúLTIPLA". São providenciados métodos para identificarcompostos, que modulam a atividade de uma proteína quinase delinhagem múltipla e promovem a sobrevivência da célula ou morteda célula, compreendendo as etapas de contatar a célulacontendo a proteína quinase de linhagem múltipla com ocomposto, determinar, se o composto diminui a atividade daproteína quinase de linhagem múltipla, e determinar, se o compostopromove a sobrevivência da célula. Também são providenciadosmétodos para identificar compostos que podem ser de utilidade notratamento de distúrbios neurodegenerativos, e/ou inflamação.Também se providencia métodos para modulação da atividade deuma proteína quinase de linhagem múltipla compreendendo ocontato da proteína ou uma célula contendo a proteína com umcomposto indeno- ou indolo- da invenção. São tambémprovidenciados métodos de tratamento de distúrbiosneurodegenerativos e/ou inflamação.
BR9913190-0A 1998-08-26 1999-08-18 Modulação de proteìnas quinase de linhagemmúltipla BR9913190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26
PCT/US1999/018864 WO2000013015A1 (en) 1998-08-26 1999-08-18 Modulating multiple lineage kinase proteins

Publications (1)

Publication Number Publication Date
BR9913190A true BR9913190A (pt) 2001-12-11

Family

ID=22266038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913190-0A BR9913190A (pt) 1998-08-26 1999-08-18 Modulação de proteìnas quinase de linhagemmúltipla

Country Status (24)

Country Link
EP (1) EP1105728B1 (pt)
JP (1) JP2002523780A (pt)
KR (1) KR100700028B1 (pt)
CN (3) CN1879617A (pt)
AT (1) ATE293254T1 (pt)
AU (1) AU765637B2 (pt)
BG (1) BG105360A (pt)
BR (1) BR9913190A (pt)
CA (1) CA2339539A1 (pt)
CZ (1) CZ2001701A3 (pt)
DE (1) DE69924738T2 (pt)
DK (1) DK1105728T3 (pt)
EA (2) EA200500934A1 (pt)
ES (1) ES2241316T3 (pt)
HU (1) HUP0103079A3 (pt)
NO (1) NO20010389L (pt)
NZ (1) NZ509612A (pt)
PL (1) PL346246A1 (pt)
PT (1) PT1105728E (pt)
SK (1) SK2542001A3 (pt)
TR (2) TR200100589T2 (pt)
UA (1) UA74772C2 (pt)
WO (1) WO2000013015A1 (pt)
ZA (1) ZA200100835B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
HRP20030162A2 (en) * 2000-08-11 2005-12-31 Cephalon Modulating multiple lineage kinase proteins
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
WO2009098196A2 (en) * 2008-02-04 2009-08-13 Biofocus Dpi B.V. Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases.
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
KR20110081862A (ko) * 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
BR112012009257A2 (pt) * 2009-10-22 2016-11-22 Genentech Inc modulação de degeneração de axônio.
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US9539259B2 (en) 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
DE69924738T2 (de) 2006-03-02
EP1105728A1 (en) 2001-06-13
CA2339539A1 (en) 2000-03-09
KR100700028B1 (ko) 2007-03-27
AU765637B2 (en) 2003-09-25
TR200100589T2 (tr) 2001-07-23
DK1105728T3 (da) 2005-08-08
DE69924738D1 (de) 2005-05-19
CN1879617A (zh) 2006-12-20
HUP0103079A3 (en) 2004-03-01
UA74772C2 (en) 2006-02-15
HK1037722A1 (en) 2002-02-15
JP2002523780A (ja) 2002-07-30
PT1105728E (pt) 2005-07-29
EA006648B1 (ru) 2006-02-24
SK2542001A3 (en) 2002-06-04
EA200500934A1 (ru) 2006-04-28
BG105360A (bg) 2001-10-31
PL346246A1 (en) 2002-01-28
TR200400635T2 (tr) 2005-10-21
CZ2001701A3 (cs) 2002-04-17
ES2241316T3 (es) 2005-10-16
NO20010389L (no) 2001-04-02
EP1105728B1 (en) 2005-04-13
ATE293254T1 (de) 2005-04-15
CN1314999A (zh) 2001-09-26
NZ509612A (en) 2003-10-31
CN1589788A (zh) 2005-03-09
HUP0103079A2 (hu) 2001-12-28
AU5679399A (en) 2000-03-21
WO2000013015A1 (en) 2000-03-09
KR20010103573A (ko) 2001-11-23
NO20010389D0 (no) 2001-01-23
WO2000013015A8 (en) 2000-05-11
EA200100278A1 (ru) 2002-06-27
ZA200100835B (en) 2002-06-26
CN1206535C (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
AU8101698A (en) Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
ATE333645T1 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
DE69432055D1 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
NZ332954A (en) Use of BPI protein products to treat humans with hemorrhage due to trauma
DE69736858D1 (de) Unsterbliche vogelzellen
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
BR0113266A (pt) Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
ATE417926T1 (de) Zusammensetzungen zur modulierung der länge von telomeren
WO2004109290A3 (en) Methods for identifying modulators of kinesin activity
ATE346939T1 (de) Dsp-3, eine phosphatase mit zwei spezifizitäten
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
DE69738945D1 (de) Rken
DE59910697D1 (de) Verwendung von D-Galaktose zur Verhinderung von Nekrosen
EA200200321A1 (ru) Апоптин-ассоциированный белок
DE69626010D1 (de) Verwendung von tropolon derivate zur hemmung des inositmono phosphatase
ECSP992875A (es) Inhibidores de la proteina /tirosina/ cinasa /de imidazopiracina sustituidas con heterociclo
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM OS ARTS. 8O E 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.